A1SN34 logo

Ascendis Pharma BOVESPA:A1SN34 Stock Report

Last Price

R$48.42

Market Cap

R$41.9b

7D

0%

1Y

60.4%

Updated

08 Jun, 2024

Data

Company Financials +

Ascendis Pharma A/S

BOVESPA:A1SN34 Stock Report

Market Cap: R$41.9b

Ascendis Pharma A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ascendis Pharma
Historical stock prices
Current Share PriceUS$48.42
52 Week HighUS$52.90
52 Week LowUS$27.62
Beta0.59
1 Month Change0%
3 Month Change0.88%
1 Year Change60.44%
3 Year Changen/a
5 Year Changen/a
Change since IPO36.97%

Recent News & Updates

Recent updates

Shareholder Returns

A1SN34BR BiotechsBR Market
7D0%2.5%-1.0%
1Y60.4%1.8%-2.4%

Return vs Industry: A1SN34 exceeded the BR Biotechs industry which returned 1.8% over the past year.

Return vs Market: A1SN34 exceeded the BR Market which returned -2.4% over the past year.

Price Volatility

Is A1SN34's price volatile compared to industry and market?
A1SN34 volatility
A1SN34 Average Weekly Movementn/a
Biotechs Industry Average Movement8.7%
Market Average Movement4.6%
10% most volatile stocks in BR Market9.2%
10% least volatile stocks in BR Market2.1%

Stable Share Price: A1SN34 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine A1SN34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006879Jan Mikkelsenascendispharma.com

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Ascendis Pharma A/S Fundamentals Summary

How do Ascendis Pharma's earnings and revenue compare to its market cap?
A1SN34 fundamental statistics
Market capR$41.89b
Earnings (TTM)-R$2.88b
Revenue (TTM)R$1.89b

22.1x

P/S Ratio

-14.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A1SN34 income statement (TTM)
Revenue€329.02m
Cost of Revenue€47.34m
Gross Profit€281.68m
Other Expenses€783.25m
Earnings-€501.57m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-8.75
Gross Margin85.61%
Net Profit Margin-152.44%
Debt/Equity Ratio-239.8%

How did A1SN34 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.